Sirtuin 3‐mediated deacetylation of acyl‐ CoA synthetase family member 3 by protocatechuic acid attenuates non‐alcoholic fatty liver disease

Ruimin Sun,Xiaohui Kang,Yan Zhao,Zhanyu Wang,Ruiwen Wang,Rong Fu,Yang Li,Yan Hu,Zhecheng Wang,Wen Shan,Junjun Zhou,Xiaofeng Tian,Jihong Yao
DOI: https://doi.org/10.1111/bph.15159
IF: 7.3
2020-08-09
British Journal of Pharmacology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Hepatic fatty acid metabolism disorder, a key pathogenic mechanism underlying nonalcoholic fatty liver disease (NAFLD), is associated with the hyperacetylation of mitochondrial enzymes. Acyl‐CoA synthetase family member 3 (ACSF3), which is involved in the regulation of fatty acid metabolism, was predicted to contain lysine acetylation sites related to the mitochondrial deacetylase sirtuin 3 (SIRT3). The purpose of this study was to explore the underlying mechanism by which SIRT3 deacetylates ACSF3 in NAFLD and the protective effect of the natural phenolic compound protocatechuic acid (PCA) against fatty acid metabolism disorder via the SIRT3/ACSF3 pathway.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>The role of PCA and its molecular mechanism in NAFLD were detected in rats and SIRT3‐knockout mice fed a high‐fat diet (HFD) and in AML‐12 cells treated with palmitic acid (PA).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Pharmacological treatment with PCA significantly attenuated HFD‐induced fatty acid metabolism disorder in NAFLD. Molecular docking assays showed that PCA specifically bound SIRT3 as a substrate and increased SIRT3 protein expression. However, the protective role of PCA was abolished by SIRT3 knockdown, which increased ACSF3 expression and exacerbated fatty acid metabolism disorder. Mechanistically, SIRT3 was shown to specifically regulate the acetylation and degradation of ACSF3, which govern the capacity of ACSF3 to mediate fatty acid metabolism disorder during NAFLD.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>SIRT3‐mediated ACSF3 deacetylation is a novel molecular mechanism in NAFLD therapy, and PCA confers protection against HFD‐ and PA‐induced hepatic fatty acid metabolism disorder through the SIRT3/ACSF3 pathway.</p></section>
pharmacology & pharmacy
What problem does this paper attempt to address?